Oramed Pharmaceuticals (ORMP) Non-Current Deffered Revenue (2016 - 2025)

Oramed Pharmaceuticals' Non-Current Deffered Revenue history runs 10 years deep, the most recent figure standing at $2.0 million for Q4 2025.

• Quarterly Non-Current Deffered Revenue fell 50.0% year-over-year to $2.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.0 million (down 50.0% YoY) and the FY2025 annual result came in at $2.0 million, down 50.0% from the prior year.
• Non-Current Deffered Revenue was $2.0 million for Q4 2025 at Oramed Pharmaceuticals, roughly flat from $2.0 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $5.6 million in Q1 2021 and bottomed at $2.0 million in Q2 2022.
• A 5-year average of $3.6 million and a median of $4.0 million in 2022 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2023 — Non-Current Deffered Revenue surged 100.0% — and 2025, when it plunged 50.0%.
• Oramed Pharmaceuticals' Non-Current Deffered Revenue stood at $3.6 million in 2021, then grew by 12.04% to $4.0 million in 2022, then changed by 0.0% to $4.0 million in 2023, then changed by 0.0% to $4.0 million in 2024, then plunged by 50.0% to $2.0 million in 2025.
• Business Quant data shows ORMP's Non-Current Deffered Revenue at $2.0 million in Q4 2025, $2.0 million in Q3 2025, and $2.0 million in Q2 2025.